Automated Detection of Arm-Level Alterations for Individual Cancer Patients
By LabMedica International staff writers Posted on 25 Sep 2021 |

The Quant-iT 1X dsDNA HS (High-Sensitivity) Assay Kit is designed to make DNA quantitation easy and accurate. The assay is highly selective for double-stranded DNA (dsDNA) over RNA (Photo courtesy of Thermo Fisher Scientific)
Copy number alterations (CNAs) can be gains, losses, or loss of heterozygosity (LOH) of a chromosome segment. Based on the length of the altered segment, they are crudely classified as “focal alterations” and “arm-level alterations”.
While genome-wide techniques to detect arm-level alterations are gaining momentum in hospital laboratories, the high precision and novelty of these techniques pose new challenges. There is no consensus on the definition of an arm-level alteration and a lack of tools to compute them for individual patients.
Clinical Scientists at the Geneva University Hospital (Geneva, Switzerland) performed OncoScan FFPE assays (Thermo Fisher Scientific, Waltham, MA, USA) for more than 400 patients as part of the routine laboratory analyses from 2016 to 2018. The median age at the time of analysis was 59 years for females and 60 years for males. Among these 376 samples, 25 were manually selected to validate the method against the expert annotations from the clinical report. Centered on the content of the clinical reports, the selection was made to represent a diverse range of arm-level alterations in terms of chromosomal distribution, CNA type (Gain versus. Loss of copies), tumor ploidy, and the number of arms altered.
Genomic DNA was purified from Formalin-Fixed Paraffin-Embedded (FFPE) tumor tissues using QIAamp DNA FFPE Tissue Kit (QIAGEN (Hilden, Germany) and quantified using the Quant-iT dsDNA HS Assay Kit (Life Technologies, CA, USA). The arrays were stained in GeneChip Fluidics Station (Thermo Fisher Scientific) and scanned using the Gene Chip scanner. The OncoScan assay has a genome-wide resolution of 300Kbp and an even finer 50-100Kbp resolution on ∼ 900 cancer genes.
The team observed a bimodal distribution of the percentage of bases with CNAs within a chromosomal arm, with the second peak starting at 90% of arm length. They tested two approaches for the definition of arm-level alterations: sum of altered segments (SoS) >90% or the longest segment (LS) >90%. The approaches were validated against expert annotation of 25 clinical cases. The SoS method outperformed the LS method with a higher concordance (SoS: 95.2 %, LS: 79.9 %). Some of the discordances were ultimately attributed to human error, highlighting the advantages of automation. The investigators observed that both computational approaches (SoS and LS) showed a high number of arm-level alterations (Gain (27), Loss (14) and LOH (8)), which were missed by the manual annotation, but detected by this approach.
The authors concluded that their computational method is highly accurate and robust for detecting copy number alterations across diverse cancer types in a clinical setting. The method performs as accurately as human experts, but at a fraction of the time. A software tool also increases reliability, as typographic and annotation errors were observed in some manually curated cases. The method and tool they described are now routinely used in the Department of Clinical Pathology at the Geneva University Hospitals and are available to the community. The study was published on August 25, 2021 in The Journal of Molecular Diagnosis.
While genome-wide techniques to detect arm-level alterations are gaining momentum in hospital laboratories, the high precision and novelty of these techniques pose new challenges. There is no consensus on the definition of an arm-level alteration and a lack of tools to compute them for individual patients.
Clinical Scientists at the Geneva University Hospital (Geneva, Switzerland) performed OncoScan FFPE assays (Thermo Fisher Scientific, Waltham, MA, USA) for more than 400 patients as part of the routine laboratory analyses from 2016 to 2018. The median age at the time of analysis was 59 years for females and 60 years for males. Among these 376 samples, 25 were manually selected to validate the method against the expert annotations from the clinical report. Centered on the content of the clinical reports, the selection was made to represent a diverse range of arm-level alterations in terms of chromosomal distribution, CNA type (Gain versus. Loss of copies), tumor ploidy, and the number of arms altered.
Genomic DNA was purified from Formalin-Fixed Paraffin-Embedded (FFPE) tumor tissues using QIAamp DNA FFPE Tissue Kit (QIAGEN (Hilden, Germany) and quantified using the Quant-iT dsDNA HS Assay Kit (Life Technologies, CA, USA). The arrays were stained in GeneChip Fluidics Station (Thermo Fisher Scientific) and scanned using the Gene Chip scanner. The OncoScan assay has a genome-wide resolution of 300Kbp and an even finer 50-100Kbp resolution on ∼ 900 cancer genes.
The team observed a bimodal distribution of the percentage of bases with CNAs within a chromosomal arm, with the second peak starting at 90% of arm length. They tested two approaches for the definition of arm-level alterations: sum of altered segments (SoS) >90% or the longest segment (LS) >90%. The approaches were validated against expert annotation of 25 clinical cases. The SoS method outperformed the LS method with a higher concordance (SoS: 95.2 %, LS: 79.9 %). Some of the discordances were ultimately attributed to human error, highlighting the advantages of automation. The investigators observed that both computational approaches (SoS and LS) showed a high number of arm-level alterations (Gain (27), Loss (14) and LOH (8)), which were missed by the manual annotation, but detected by this approach.
The authors concluded that their computational method is highly accurate and robust for detecting copy number alterations across diverse cancer types in a clinical setting. The method performs as accurately as human experts, but at a fraction of the time. A software tool also increases reliability, as typographic and annotation errors were observed in some manually curated cases. The method and tool they described are now routinely used in the Department of Clinical Pathology at the Geneva University Hospitals and are available to the community. The study was published on August 25, 2021 in The Journal of Molecular Diagnosis.
Related Links:
Geneva University Hospital
Thermo Fisher Scientific
QIAGEN
Life Technologies
Latest Molecular Diagnostics News
- Newly-Cleared Technology a Game Changer for Diagnosis of Lyme Disease
- Innovative Liquid Biopsy Test Uses RNA to Detect Early-Stage Cancer
- Rapid Tests for Chagas Disease Improves Diagnostic Access
- Simple Blood Test to Predict Alzheimer’s Clinical Progression in Earliest Stages
- Saliva Test Could Identify People Genetically Susceptible to Type 2 Diabetes
- Pioneering Analyzer with Advanced Biochip Technology Sets New Standard in Lab Diagnostics
- RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia
- New Technique for Measuring Acidic Glycan in Blood Simplifies Schizophrenia Diagnosis
- Injury Molecular Fingerprint Enables Real-Time Diagnostics for On-Site Treatment
- Blood Test Could Predict Likelihood of Breast Cancer Spreading to The Bone
- New Infectious Disease Analytics Platform Speeds Up Clinical Decision-Making at POC
- Genetic Test Could Predict Poor Outcomes in Lung Transplant Patients
- Breakthrough Blood Test Enables Early Pancreatic Cancer Detection
- Genomic Testing in NICU Reduces Missed Diagnoses
- New Genetic Test Improves Diabetes Prediction and Classification
- New Blood Test for Leukemia Risk Detection Could Replace Bone Marrow Sampling
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment
Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Tool Enhances Interpretation of Tissue Samples by Pathologists
Malignant melanoma, a form of skin cancer, is diagnosed by pathologists based on tissue samples. A crucial aspect of this process is estimating the presence of tumor-infiltrating lymphocytes (TILs), immune... Read more
AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
Hepatocellular carcinoma (HCC), a common type of liver cancer, is difficult to diagnose early and accurately due to the limitations of current diagnostic methods. Glycans, carbohydrate structures present... Read moreTechnology
view channel
Low-Cost Biosensing Technology Detects Disease Biomarkers in Minutes
Rapid at-home tests for diseases like COVID-19 have become increasingly popular for their convenience, but they come with a major drawback: they are less sensitive than the tests performed in medical settings.... Read more
AI Tool Could Help Identify Specific Gut Bacterial Targets for Treatment of Diseases
The human body hosts trillions of bacteria, particularly in the gut, which have a significant role in digestion and various other aspects of health. These gut bacteria produce a variety of metabolites... Read moreIndustry
view channel
Quanterix Completes Acquisition of Akoya Biosciences
Quanterix Corporation (Billerica, MA, USA) has completed its previously announced acquisition of Akoya Biosciences (Marlborough, MA, USA), paving the way for the creation of the first integrated solution... Read more
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more